Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
申请人:SCHERING CORPORATION
公开号:EP0068378A1
公开(公告)日:1983-01-05
The invention relates to imidazo[1.2-a]pyridines and pyrazines of the general formula
wherein B is CH or N: and includes 2,3-dihydro-, 5,6,7,8-tetrahydro-, 2,3,5,6,7,8-hexahydro-analogues and salts of such compounds. The invention also relates to processes for preparing such compounds and to pharmaceutical compositions containing them. The compounds are antisecretory and cytoprotective agents and are particularly useful in the treatment of ulcer diseases.
本发明涉及通式中 B 为 CH 或 N 的咪唑并[1.2-a]吡啶和吡嗪,包括 2,3-二氢-、5,6,7,8-四氢-、2,3,5,6,7,8-六氢-类似物和这类化合物的盐。 本发明还涉及制备这类化合物的工艺和含有这类化合物的药物组合物。 这类化合物是抗分泌物和细胞保护剂,特别适用于治疗溃疡病。
US4450164A
申请人:——
公开号:US4450164A
公开(公告)日:1984-05-22
Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines
作者:James J. Kaminski、James A. Bristol、Chester Puchalski、Raymond G. Lovey、Arthur J. Elliott、Henry Guzik、Daniel M. Solomon、David J. Conn、Martin S. Domalski
DOI:10.1021/jm00145a006
日期:1985.7
A novel class of antiulcer agents, the substituted imidazo[1,2-a]pyridines, is described. The present compounds are not histamine (H2) receptor antagonists nor are they prostaglandin analogues, yet they exhibit both gastricantisecretory and cytoprotective properties. The mechanism of gastricantisecretory activity may involve inhibition of the H+/K+-ATPase enzyme. Structure-activity studies led to
描述了新型的抗溃疡剂,取代的咪唑并[1,2-a]吡啶。本发明的化合物既不是组胺(H 2)受体拮抗剂,也不是前列腺素类似物,但它们既具有胃分泌作用又具有细胞保护作用。胃抗分泌活性的机制可能涉及抑制H + / K + -ATPase酶。结构活性研究导致鉴定出3-(氰基甲基)-2-甲基-8-(苯甲氧基)咪唑并[1,2-a]吡啶,SCH 28080(27),已被选择用于进一步开发和临床评价。